Menu

Search

Search
Enter an event title or description
Select an event type
Select a region
Select a topics

CONGRESS 2023 - From Biomedical Scientist to the Blood Stocks Management Scheme: Life after the laboratory!

28/09/2023
There are many job roles and opportunities available to biomedical scientists outside of the laboratory, but what does a biomedical scientist do working within the Blood Stocks Management Team?

Learn about a different role, the transferable skills that are required and how this role is different from working in a laboratory environment. Why is this role important to Blood Transfusion laboratories and is it beneficial having a biomedical scientist as part of the team?

CONGRESS 2023 - Future: Preparedness planning & what might come next

28/09/2023
Future: Preparedness planning & what might come next

CONGRESS 2023 - Getting it Right First Time

28/09/2023
Getting it Right First Time

CONGRESS 2023 - High Sensitivity Troponin in the Community

28/09/2023
High Sensitivity Troponin in the Community

CONGRESS 2023 - Implementation of Blood on Board: A laboratory perspective

28/09/2023
The Air Ambulance covering Derbyshire, Leicestershire and Rutland first approached Blood Transfusion in February 2021 to discuss the idea of them being able to carry blood on the aircraft so they can carry out lifesaving transfusions at the roadside. In the previous months the medics on board had been documenting those patients they had attended that they thought would have benefited from being transfused at the scene of an injury.

The majority of these were road traffic accidents and stabbings where blood loss had led to severe morbidity or even mortality. After months of meetings discussing what equipment was needed (e.g. blood boxes, temperature monitoring devices, storage etc.), finances, validation procedures and trialling the process we finally started providing blood on board in February 2022.

CONGRESS 2023 - Implementation of the Patient Safety Incident Response Framework (PSIRF): an NHS trust perspective

28/09/2023
The presentation gives an overview of the NHS Patient Safety Incident Response Framework, it’s principles and requirements. There is also a brief summary of the Systems Engineering Initiative for Patient Safety (SEIPS) and how this is different to previous models of investigation. The presentation then focusses on how PSIRF has been implemented at Northumbria Healthcare, an acute and community provider in the North East of England, with a focus on the phased implementation approach used by the PSIRF leads. The speaker will also cover the challenges in the implementation to date and the successes experienced so far.

CONGRESS 2023 - In vitro studies of antiviral treatment options for important human pathogens

28/09/2023
This presentation will give delegates an introduction to important human viruses, their treatment with antivirals and possibilities for preventing antiviral resistance. Implications of recently identified metabolic capping of hepatitis C virus.

CONGRESS 2023 - In-house tests to CE marked - Impact on the laboratory (Debate – impact on laboratory vs commercial company)

28/09/2023
The IVDR is the new regulatory instrument for placing IVDs on the European market. The aims of the IVDR are to provide a robust, transparent and sustainable IVD framework, harmonize divergence in implementation (as experienced with the IVDD) and most importantly to increase patient safety. The document runs to 156 pages (compared to 43 for the IVDD, containing 114 articles and 15 annexes. The IVDR places more emphasis on the economic operators (actors) involved in the IVD supply chain, from the manufacturer to the customer.

Manufacturers have the obligations to design and manufacture products in compliance with the IVDR; evaluate product performance and manage risk, have a Quality Management System, create and maintain product technical documentation, conduct post market surveillance, and implement field safety corrective actions. One of the biggest changes with IVDR is the introduction of a new rules-based approach for product classification. Under IVDR, Notified Bodies perform conformity assessment on 80% of IVDs (compared to 20% under the IVDD, which becomes stricter as the risk class increases. There are also enhanced concepts for performance evaluation and clinical evidence.

Under the IVDR there is a requirement to state the clinical purpose in the intended use. Thus, in order to comply with the new regulation, manufacturers must revise all intended purpose statements in product labelling. Further, there is the obligation to gather a large amount of data to evaluate both analytical and clinical performance. Manufacturers are required to continually evaluate performance across the whole product lifecycle through post market surveillance and vigilance, with reports for the highest-risk devices uploaded to the new EUDAMED database on an annual basis.

CONGRESS 2023 - Introduction to the UKAS ISO 15189:2022 transition (Thursday)

28/09/2023
This session provides an overview of the key changes to the ISO 15189 standard and explains the UKAS transition process including deadlines and actions to be taken by accredited organisations.

The same session is being run on Monday, Tuesday and Thursday to ensure as many delegates as possible are able to attend.

CONGRESS 2023 - ISO 15189:2022 Q&A (Thursday)

28/09/2023
ISO 15189:2022 Q&A (Thursday)
  1. 1
  2. ...
  3. 4
  4. 5
  5. 6
  6. 7
  7. 8
  8. 9
  9. 10
  10. 11
  11. 12
  12. 13
  13. ...
  14. 118